CA2943808C — Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use
Assigned to Day One Biopharmaceuticals Inc · Expires 2022-08-16 · 4y expired
What this patent protects
The invention relates to a pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt thereof for the treatment of cancer and a process for its preparation. The invention also relates to administering the pharmaceutical composition to a patient accordi…
USPTO Abstract
The invention relates to a pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt thereof for the treatment of cancer and a process for its preparation. The invention also relates to administering the pharmaceutical composition to a patient according to an intermittent dosing regimen.
Drugs covered by this patent
- Ojemda (TOVORAFENIB) · Day One Biopharms
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.